Treatment failures can result in a spectrum of problems for patients with hemophilia. Here’s some guidance on choosing the right therapy.
Study reveals growing acceptance of value-based payments among family physicians, but barriers still exist.
The benefits and drawbacks of predictive modeling in end-of-life care decision making.
Shift represents growing understanding of value of genetic testing for cancers. Find out who is receiving the test and why.
Corporate giants Amazon, Berkshire Hathaway, and JPMorgan Chase, partner to shake things up in U.S. employee healthcare.
Two new studies reveal that cost-restraints can keep patients from accessing life-preserving cancer drugs.
In partnership with the several big-name cancer centers, one company has commenced clinical trials. Find out how this cancer vaccine would work.
Reducing readmissions for chronic obstructive pulmonary disease (COPD) is an ongoing challenge for healthcare systems. Here’s how one is successful.
From State-led programs to innovative pharmacist-hospital partnerships, these programs are fighting to quell the epidemic.
How are generic prices changing, how will biosimilars impact costs, and what changes out of Washington should healthcare executives watch? Economics guru Joe Fuhr weighs in.